Immunservice is a biopharmaceutical company addressing orphan disease indications as well as large market indication areas, especially those of high unmet medical need.Immunservice's biomimetic approach translates human immune hormones into well tolerated and highly effective marketable drugs that improve survival and quality of life in patients.Biomimetic therapy has the clear potential to cure patients with cancer, even those who are in urgent need and have little or no treatment alternatives.

Argenes, Inc. is a Japanese bio-venture established in April 2004 focusing primarily on the development of biopharmaceuticals and molecular targeting therapeutics, including anti-rheumatoid arthritis (RA), and anti-osteoarthritis. Currently, the company's most innovatory prospective candidate for the treatment of RA is the drug anti-Fas mAb ARG098. The company operate preclinical and clinical studies as well as manufacturer pharmaceuticals through managing of CRO and CMO. At Argenes, Inc. the company continually seek to expand globally through creating alliances and through licensing out development rights and marketing rights.

Kinexis, Inc. is a life science R&D company targeting pathology-linked oligomeric conformations of amyloid proteins involved in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and prion (Creutzfeld-Jakob) disease. Its strategy is to leverage a revenue-generating product stream through sponsored research and by forming relationships with major pharmaceutical and biotechnology companies. Kinexis' technology aims to allow generation of antibody responses specific for cytotoxic conformations of multiple amyloid proteins. Kinexis is commercializing its technology through development of biopharmaceutical products based on active immunization, passive immunotherapy, and small molecule screening strategies. Using its immunization technology, Kinexis has already identified product opportunities for Alzheimer's disease where active immunization and passive immunotherapy strategies have yielded dramatic pharmacological effects in animal models.

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

Bikam supplies all kinds of scientific and professional literature. It offers a subscription order for government and non-government organizations, commercial representatives, higher educational institutions, and more. It was founded in 1996 and is based in Sofia, Bulgaria.

is discovering compounds that selectively inhibit replication of the hepatitis C virus, and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. They aim to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate.